First-line Immunotherapy Shows Promise in Advanced BCC
Patients with advanced basal cell carcinoma (BCC) may benefit from receiving immunotherapy earlier in the course of treatment, according to a new study presented at the European Society for Medical Oncology (ESMO) annual meeting in Berlin, Germany.